Learn about our comprehensive antibody validation methods to ensure monospecificity.  Antibody Validation>>

IGF1R alpha / CD221 Antibody [24-60]

In Stock
Catalog Number Formulation Size Price
3480-MSM6-P0
Purified Ab with BSA and Azide at 200ug/ml
20ug
$229.00
3480-MSM6-P1
Purified Ab with BSA and Azide at 200ug/ml
100ug
$519.00
3480-MSM6-P1ABX
Purified Ab WITHOUT BSA and Azide at 1.0mg/ml
100ug
$519.00
Flat Rate Domestic: $60 | Orders outside the US - Contact Us for Order Information | Ships next business day

Applications & Dilutions

Applications Tested Dillution Protocol
Immunofluorescence (IF)
1-3ug/ml

Summary

This antibody is specific for the human insulin-like growth factor 1 receptor (IGF1R). It recognizes the extracellular portion of the receptor, specifically an epitope in the cysteine rich domain of the alpha subunit, between amino acids 184 and 283. It does not cross-react with rat or mouse IGF1R or human insulin receptors in co-precipitation or immunodepletion assays.

The ability of this antibody to bind human IGF1R has been confirmed in IGF1 binding assays using both IG1FR-overexpressing IGF1R/3T3 cells and soluble receptors (Soos et al, 1992). This antibody efficiently precipitates human IGF1R solubilised from IGF1R/3T3 cells (Soos et al, 1992) and human placental membranes (Bailyes et al, 1997), and has been used in immunoprecipitation analysis of 293 cells transfected with IGF1R or chimeric IGF1R-insulin receptor (IR) constructs (Schumacher et al, 1993). When immobilised, this antibody has been shown to remove essentially all soluble, IGF1R/3T3-derived IGF1R (Soos et al, 1992) and human placental membrane-derived IGF1R (Soos et al, 1993) in immunodepletion experiments. This antibody strongly inhibits IGF1 binding to its receptor (Soos et al, 1992), and has been shown to suppress IGF1-mediated stimulation of skin fibroblast proliferation (Okubo et al 2003).

Product Properties & Targets

Antibody Type
Host
Mouse
Species Reactivity
Isotype / Light Chain
IgG2a / Kappa
Cellular Localization
Cell membrane
Gene Name
Positive Control
Human breast carcinoma or colon carcinoma.
Immunogen
IGF-1R/3T3 mouse fibroblasts transfected with human type I IGF-receptor cDNA
Alternate Names
Insulin-like growth factor 1 receptor, Insulin-like growth factor I receptor, CD221 antigen; IGF 1 receptor; IGF 1R; IGFIR; IGFIRC; IGFR; Insulin like growth factor 1 receptor precursor; Insulin-like growth factor 1 receptor beta chain; JTK13; Soluble IGF1R variant 1; Soluble IGF1R variant 2

Database Links

Entrez Gene ID
SwissProt

Additional Information

Clone
24-60
Chromosome Location
15q26.3
Mol. Weight of Antigen
130kDa (IGF-1R); 97kDa (IGF-1R); 200kDa (pro-IGF-1R)

Functions

  • Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGFIR through phosphorylation and inactivation of BAD. In parallel to PI3K-driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT). Phosphorylation of JAK proteins can lead to phosphorylation/activation of signal transducers and activators of transcription (STAT) proteins. In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be activated by the IGF1R. IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5/ASK1, which is able to directly associate with the IGF1R.
  • When present in a hybrid receptor with INSR, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.

Key References

  • Soos et al. A panel of monoclonal antibodies for the type I insulin-like growth factor receptor. Epitope mapping, effects on ligand binding, and biological activity. J Biol Chem. 1992 Jun 25;267(18):12955-63. PMID:1377676

PubMed Links

Storage & Stability

Antibody with azide - store at 2 to 8 °C. Antibody without azide - store at -20 to -80 °C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Limitations

This antibody is available for research use only and is not approved for use in diagnosis.

Supplied as

200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.

Warranty

There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.

Reviews

There are no reviews yet.

Be the first to review “IGF1R alpha / CD221 Antibody”

Your email address will not be published. Required fields are marked *

PARTNERSHIP OPPORTUNITIES

We hold Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.

LETS TALK